Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference

Enveric Biosciences (NASDAQ: ENVB) reported Q2 2026 results and a corporate update. The company said EB-003 IND-enabling work advanced, including genotoxicity studies, and preclinical assays suggested a non-hallucinogenic and non-photoreactive profile. Enveric also received USPTO patent approvals and raised about $5.0M gross in a private placement plus $1.5M from warrant exercises. Net loss was $3.0M, cash $8.3M.

Enveric Biosciences, Inc. (ENVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026 EB-003 Development Highlights: ● Continued advancing IND-enabling studies supporting the planned submission of an Investigational New Drug (IND) application for EB-003

Michael Burry, known for his 2007 real estate market bet, has short positions in Oracle (ORCL), Palantir (PLTR), and Nebius (NBIS). He reduced bets against NVDA and PLTR. Burry's options suggest an AI crash by year-end, but Nvidia's GPU deals and Hugging Face acquisition indicate strong AI demand. Palantir's government contracts may boost revenue.

Jefferies launched healthcare REIT coverage, favoring senior housing due to demographics and limited supply. It initiated Janus Living (Buy, $36 target), Welltower (Buy, $275 target), and Ventas (Buy, $102 target) with Buy ratings, citing quality and growth. Healthpeak and Healthcare Realty Hold were rated neutral.

Halliburton has won a multi-year contract with Eni to provide well services for the Cronos gas development offshore Cyprus. The contract covers exploration and development wells in Block 6 of Cyprus’ Exclusive Economic Zone. Halliburton will offer integrated services, including drilling, well construction, and completions, using its LOGIX technologies. The contract expands Halliburton’s presence in the Eastern Mediterranean, though the value and duration were not disclosed.

Berenberg upgraded Eli Lilly to buy, raising its price target to $1,400, citing strong performance in the obesity market and potential upside in its GLP-1 drug pipeline. Shares have risen 52% over the past year, and the analyst expects further growth. Eli Lilly makes Mounjaro and Zepbound, with additional drugs in development. 27 of 34 analysts recommend buying the stock. Shares gained over 1% in premarket trading.